Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shilpa MedicareNSE:SHILPAMED -2.76%76 PEG Ratio is 4.58 as of Jul. 18, 2026, which is 43% above its 10-year median of 3.20. GuruFocus rates NSE:SHILPAMED with a GF Score™ of 76/100 and a GF Value™ of ₹387.78 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 348 Drug Manufacturers companies, Shilpa Medicare ranks worse than 78.45% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Shilpa Medicare's PEG Ratio or its related term are showing as below:
NSE:SHILPAMED'
s PEG Ratio Range Over the Past 10 Years
Min: 0.99 Med: 3.2 Max: 76.09
Current: 4.58
During the past 13 years, Shilpa Medicare's highest PEG Ratio was 76.09. The lowest was 0.99. And the median was 3.20.
NSE:SHILPAMED's PEG Ratio is ranked worse than 78.45% of 348
companies
in the Drug Manufacturers industry
Industry Median: 1.715
vs NSE:SHILPAMED: 4.58
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Shilpa Medicare (NSE:SHILPAMED) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Shilpa Medicare PEG Ratio Related Terms
Shilpa Medicare PEG Ratio Historical Data
* Premium members only.
The historical data trend for Shilpa Medicare's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shilpa Medicare's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shilpa Medicare PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shilpa Medicare's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Shilpa Medicare's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Shilpa Medicare (NSE:SHILPAMED) has a PEG Ratio of 4.58 as of Jul. 18, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Shilpa Medicare and its competitors. This is 43% above median its historical median of 3.20. Over the past decade, Shilpa Medicare's PEG Ratio has ranged from 0.99 to 76.09. According to the industry distribution chart, Shilpa Medicare ranks #273 out of 348 companies in the Drug Manufacturers industry, placing it in the top 78.4%.
Is Shilpa Medicare's PEG Ratio too high?
Shilpa Medicare's current PEG Ratio of 4.58 is 43% above median its 10-year median of 3.20. Over the past 10 years, this metric has ranged from a low of 0.99 to a high of 76.09. The Drug Manufacturers industry median PEG Ratio is 1.72. Shilpa Medicare's value of 4.58 is 167.1% above this industry median. Based on the distribution chart, Shilpa Medicare ranks #273 out of 348 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shilpa Medicare has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shilpa Medicare ranks #273 out of 348 companies for PEG Ratio. This places Shilpa Medicare in the lower half of its industry. The industry median PEG Ratio is 1.72. Shilpa Medicare's value of 4.58 is 167.1% above this benchmark. Historically, Shilpa Medicare's own PEG Ratio has ranged from 0.99 to 76.09 over the past decade. While the company's 10-year median is 3.20 vs. the industry median of 1.72, Shilpa Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.72, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shilpa Medicare's current PEG Ratio of 4.58 is 167.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Shilpa Medicare and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shilpa Medicare's current PEG Ratio is 4.58, which is 43% above median its own 10-year median of 3.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (NSE:SHILPAMED) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹387.78, compared to a current price of ₹620.25 — trading 59.9% above its estimated fair value. The current PEG Ratio is 4.58, which is 43% above median its 10-year median of 3.20 and 167.1% above the Drug Manufacturers industry median of 1.72. Shilpa Medicare's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Shilpa Medicare (NSE:SHILPAMED), the current PEG Ratio is 4.58 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shilpa Medicare (NSE:SHILPAMED) Overvalued in 2026?
Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued.
The current stock price of ₹620.25 is trading 59.9% above its estimated GF Value™ of ₹387.78.
GuruFocus considers Shilpa Medicare to be Significantly Overvalued.
Key valuation signals for NSE:SHILPAMED:
PEG Ratio: 4.58 (43% above median its 10-year median of 3.20)
GF Value™: ₹387.78 vs. price of ₹620.25 (59.9% above fair value)
Industry Position: 167.1% above the Drug Manufacturers median (#273 of 348)
No single metric tells the full story. See the NSE:SHILPAMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
76GF Score
Get the complete analysis for NSE:SHILPAMED
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SHILPAMED has been successfully added to your 
